Home � Products & Services � Benchmarking Reports � Product Launch � Product Launch Excellence

Win or Lose at Launch: What Separates Biopharma Launch Success from Failure

Download FREE Excerpt

ID: PSM-407

Features:

38 Info Graphics

28 Data Graphics

880+ Metrics

6 Narratives

Pages: 75

Published: 2026

Delivery Format: Shipped

License Options:
$6000 - 1 user
$18000 - Up to 5 users
$30000 - Up to 20 users

919-403-0251

Schedule a Meeting

STUDY OVERVIEW
BENCHMARK CLASS
STUDY SNAPSHOT
KEY FINDINGS
VIEW TOC AND LIST OF EXHIBITS

Biopharma product launches have grown increasingly complex, with competitive crowding, evolving payer expectations, and fragmented stakeholder landscapes creating significant risk of underperformance at market entry. Despite huge commercial investment, many launches fail to achieve early targets due to misaligned positioning, weak stakeholder education, or poor patient identification strategies - failures that compound rapidly and, as the most challenging case studies in this research demonstrate, can prove unrecoverable.

Developed by Best Practices LLC, this benchmarking research synthesizes insights from launch leaders across seven leading biopharma companies, supplemented by in-depth case analyses of six landmark launch successes: Casgevy and Lyfgenia in sickle cell gene therapy, Zolgensma in spinal muscular atrophy, Leqembi in early Alzheimer's disease, Dupixent in type 2 inflammation, and Aimovig in migraine prevention. Together, these perspectives reveal the strategic and executional factors that most reliably separate market winners from those that fall short - across both crowded established markets and novel therapeutic spaces.

The report examines launch performance across five interconnected domains:

Competitive positioning and differentiation strategy
Stakeholder-specific messaging for physicians, payers, and patients
Aggregate resource allocation from Phase III through launch
Internal execution risk
Market access infrastructure

The findings reveal a consistent pattern: launches that win are built on strategic clarity developed well before market entry, executed with discipline in the first six months, and backed by payer and access infrastructure that converts label strength into real-world patient uptake. This research will equip commercial and launch leaders with the benchmarks and frameworks to make better investment decisions, close execution gaps, and position their products for durable commercial success.

What You'll Learn From This Report:

Which competitive positioning factors most reliably drive physician trial — and how they differ across niche/novel versus established markets
How to build audience-specific messaging architectures for physicians, payers, and patients from the same clinical data set
Where pre-launch budgets are best concentrated — and which engagement tactics consistently underdeliver despite growing investment
Which internal execution failure points carry the highest risk at launch and are expected to intensify over the next 24–36 months
What the Casgevy/Lyfgenia outcome reveals about how compounding disadvantages in safety, pricing, and access become unrecoverable
How Zolgensma, Leqembi, Dupixent, Aimovig, and Enhertu each navigated differentiation, access, and stakeholder engagement — and the lessons transferable to your own launch

Industries Profiled:
Biotech; Manufacturing; Pharmaceutical; Consumer Products; Health Care; Biopharmaceutical; Clinical Research; Laboratories

Companies Profiled:
Biogen; L�kahi Therapeutics; LEO Pharma; Novartis; Servier; Vertex; Viking Therapeutics; Amgen; AstraZeneca; Daiichi Sankyo; Eisai; Genetix Biotherapeutics; Regeneron; Sanofi

Study Snapshot

Best Practices, LLC engaged 8 launch leaders across 7 leading biopharma companies through a benchmarking survey focused on recent product launches across multiple therapeutic areas. Six detailed case analyses of landmark launches were also conducted to capture additional insights on differentiation strategy, stakeholder engagement effectiveness, access infrastructure, and launch execution best practices.

Key topics covered in this report include:

Competitive Market Entry and Product Differentiation Strategy
Stakeholder-Specific Positioning for Physicians, Payers, and Patients
Pre-Launch Resource Allocation and Engagement Tactic Effectiveness
Market-Shaping Pitfalls and Internal Execution Risk
Launch Case Analogs: Gene Therapy, Neurology, Immunology, and Oncology

Key Findings

Select key insights uncovered from this report are noted below. Detailed findings are available in the full report.

Differentiation Is the Defining Battle — and the Stakes Are Rising: Roughly two-thirds of launches (63%) enter established, crowded markets where differentiation failure is rated the single highest market-shaping risk. It is also the only risk most leaders expect to intensify over the next 24–36 months, signaling that competitive pressure will not ease. Launches that win pressure-test their differentiation strategies during Phase III and build a defensible evidentiary foundation before market entry — not after.

Scientific Engagement Consistently Outperforms Digital Channels: Clinical data sharing and protocol input with thought leaders (75% highly effective) and KOL development with physicians (63%) lead all pre-launch engagement tactics. Digital and social channels consistently underperform, yet digital under-resourcing and promotional complexity are the execution risks most expected to rise over the next 24–36 months — revealing a critical misalignment between emerging investment trends and proven impact. Physician education (36%) and thought leader engagement (28%) absorb two-thirds of Phase III-to-launch budgets, and the evidence suggests this allocation is well-placed.

Access Infrastructure and Label Quality Compound — For Better or Worse: The Casgevy versus Lyfgenia outcome illustrates how compounding disadvantages — a Boxed Warning, a 41% price premium with no clinical superiority, and late Medicaid access — can render a launch commercially unrecoverable. A label advantage alone is not sufficient: Leqembi, despite receiving full FDA approval and Medicare coverage, reaches under 1% of an estimated 2 million eligible Alzheimer's patients, constrained by a 20-month GP-to-infusion referral funnel and diagnostic infrastructure gaps. Building payer strategy, outcomes-based access models, and patient identification infrastructure in advance of launch is not optional — it is the mechanism that converts label strength into real-world uptake.

Table of Contents

Sr. No.	Topic	Slide No.
I.	Strategic Imperatives for Biopharma Launch	Pg. 3
II.	Executive Summary	Pg. 7
III.	Launch Context and Product Positioning	Pg. 10
IV.	Stakeholder Engagement and Education	Pg. 17
V.	Market Pitfalls and Lessons Learned	Pg. 38
VI.	Case Analogs	Pg. 49
VII.	Participant Demographics	Pg. 73
VIII.	About Best Practices, LLC	Pg. 75

List of Charts & Exhibits

I. Executive Summary

Strategic imperatives for biopharma launch
One-page summary of study objectives, methodology, and key insights
Participating benchmark companies and branded case study analogs
Executive takeaways: differentiation, positioning, and market entry risk
Executive takeaways: engagement effectiveness, execution risk, and access outcomes

II. Launch Context and Product Positioning

Competitive situation at market entry: proportion of launches entering niche/novel vs. established markets
Factors for driving initial physician trial: ranking of diagnostic, symptom, and patient-need cues
Leqembi case: how diagnostic screening powered the AHEAD 3-45 prevention trial
Factors for driving initial physician trial by market segment (niche/novel vs. established)
Primary positioning dimensions used: overall ratings for efficacy, unmet need, and competitive claims
Zolgensma case: how Novartis communicated infant SMA's unmet need and urgency to the market

III. Stakeholder Engagement and Education

Aggregate resource allocation across key stakeholders from Phase III to launch
Aggregate resource allocation across key stakeholders from Phase III to launch by market segment (niche/novel vs. established)
Differentiating positioning for physicians: effectiveness ratings for clinical and messaging factors
Differentiating positioning for physicians by market segment (niche/novel vs. established)
Enhertu case: how DESTINY-Breast04 redefined the HER2-low patient population and drove physician adoption
Differentiating positioning for payers: effectiveness ratings for clinical, value, and access factors
Differentiating positioning for payers by market segment (niche/novel vs. established)
Casgevy/Lyfgenia case: CMS pay-for-performance model and Medicaid access for gene therapy
Differentiating positioning for patients: effectiveness ratings for clinical and experience factors
Differentiating positioning for patients by market segment (niche/novel vs. established)
Dupixent MyWay� case: four pillars of access support and adherence infrastructure
Thought leader engagement effectiveness: ratings across scientific, advisory, and digital tactics
Thought leader engagement effectiveness by market segment (niche/novel vs. established)
Payer education activity effectiveness: ratings across account, formulary, and HEOR tactics
Payer education activity effectiveness by market segment (niche/novel vs. established)
Physician education activity effectiveness: ratings across KOL, publication, and digital tactics
Physician education activity effectiveness by market segment (niche/novel vs. established)
Patient advocacy and education activity effectiveness: ratings across programs and digital channels
Patient advocacy and education activity effectiveness by market segment (niche/novel vs. established)
Aimovig case: patient-led demand generation strategy ahead of and at launch

IV. Market Pitfalls and Lessons Learned

Market-shaping pitfalls: current risk levels for differentiation failure, share-of-voice loss, and scientific publishing gaps
Market-shaping pitfalls: current risk levels by market segment (niche/novel vs. established)
Market-shaping pitfalls: anticipated change over the next 24–36 months
Market-shaping pitfalls: anticipated change by market segment (niche/novel vs. established)
Lyfgenia case: indefensible price premium and commercial outcome relative to Casgevy
Internal execution failure points: current risk levels for sales communication, field execution, and digital strategy
Internal execution failure points: current risk levels by market segment (niche/novel vs. established)
Internal execution failure points: anticipated change over the next 24–36 months
Internal execution failure points: anticipated change by market segment (niche/novel vs. established)
Top lessons learned and best practices for successful competitive market entry

V. Case Analogs

Casgevy vs. Lyfgenia: launch overview, indication, drug class, and revenue trajectory
Casgevy vs. Lyfgenia: clinical and safety label comparison driving differential physician adoption
Casgevy/Lyfgenia: scale of the Medicaid-dependent sickle cell patient population and the access challenge
Casgevy/Lyfgenia: CMS Cell & Gene Therapy Access Model — state participation, patient coverage, and outcomes tracking timeline
Lyfgenia market exit: failure analysis of compounding safety, pricing, access, and credibility disadvantages
Zolgensma: launch overview, indication, drug class, lifecycle expansions, and revenue trajectory
Zolgensma: payer education strategy and how Novartis framed the SMA gene therapy access conversation
Zolgensma: $2.125M launch price, Novartis revenue milestones, and global market expansion
Zolgensma: outcomes-based contracting structure and 5-year pay-over-time model
Leqembi: launch overview, indication, FDA approval pathway, and revenue trajectory
Leqembi: Medicare coverage path shaped by the Aduhelm precedent and CMS coverage restrictions
Leqembi: KOL and academic medical center engagement strategy driving scientific credibility and adoption
Leqembi: access barriers at launch — diagnostic infrastructure gaps and the GP-to-infusion referral funnel
Leqembi: full case summary across FDA approval, Medicare coverage, and commercial performance
Leqembi: barrier-to-unlock mapping for scaling patient identification and infusion access
Dupixent: launch overview, indication, drug class, and commercial trajectory across six indications
Dupixent: how access friction and patient affordability challenges were structured at launch
Dupixent MyWay�: four pillars of nurse educator support, insurance navigation, financial assistance, and adherence
Aimovig: launch overview, indication, CGRP mechanism, and commercial trajectory
Aimovig: two-phase patient demand generation strategy — "Speak Your Migraine" and "I Am Here" campaigns
Aimovig: launch execution — patient activation, HCP pull-through, and campaign impact at scale
Enhertu: launch overview, indication, drug class, HER2-low mechanism, and revenue trajectory
Enhertu: DESTINY-Breast04 — how one trial redefined HER2-low as a targetable population and drove physician retesting

VI. Participant Demographics

Therapeutic areas represented in the study